PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Aspirin - Atrial fibrillation
PAD Profile : Aspirin - Atrial fibrillation
Keywords :
SPAF, stroke prevention in AF, anticoagulation, vitamin K antagonist, antiplatelets, bleed, risk, ORBIT
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Apixaban
- Dabigatran etexilate
- Dronedarone hydrochloride
- Rivaroxaban
- Warfarin sodium
- Edoxaban
- Acenocoumarol
Other Indications
Additional Documents
Type
Document
Review Date
Guidelines (Local)
01 September 2020
Guidelines (Local)
01 September 2020
Guidelines (Local)
01 July 2023
Guidelines (Local)
30 June 2027
Patient resource
Information
01 January 2025
Committee Recommendations
Date
Committee Name
Narrative
02 March 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands ICS Area Prescribing Committee have agreed the use of an ORBIT-bleed risk scoring tool when considering or reviewing anticoagulant treatment in Atrial Fibrillation (AF).
06 December 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Updated Kent Surrey & Sussex Academic Health Science Network (KSS AHSN) Atrial Fibrillation pathways attached for information (See below)
03 September 2014
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Do not offer aspirin monotherapy solely for stroke prevention to people with atrial fibrillation. Further information available in NICE guidance CG180.
Associated BNF Codes
02. Cardiovascular System
02.09.00. Antiplatelet drugs